In South African PMTCT programs prioritizing ART for women with advanced HIV infection (Option A), our model-based analyses suggested that any improvement in testing rates or result-return rates will more than offset the cost of point-of-care CD4 assays, and that the benefits of POC testing will be even greater in settings where access to laboratory-based CD4 testing is limited. The gene discussed is CD4; the disease is HIV infectious disease.